Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAP3K14 (NF-κB-Inducing Kinase / NIK) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAP3K14 Recombinant Kinase Domain / Mutant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View MAP3K14 Products |
| Gene Delivery | MAP3K14 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and signaling assays. |
View MAP3K14 Products |
| Benchmark Ab | Anti-MAP3K14 Recombinant Reference Antibody Recombinant positive control for assay validation. |
View MAP3K14 Products |
| Validator | MAP3K14 siRNA Set For target knockdown verification. |
View MAP3K14 Products |
| Related Target A | LTBR (Lymphotoxin-Beta Receptor) Upstream activator of the non-canonical NF-κB pathway via MAP3K14 stabilization. |
View LTBR Products |
| Related Target B | CD40 TNF-receptor superfamily member driving MAP3K14-mediated B-cell activation. |
View CD40 Products |
| Related Target C | CHUK (IKK-alpha) Direct downstream phosphorylation substrate of MAP3K14. |
View CHUK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Screening for kinase-dependent vs. scaffolding-dependent functions | Wild-type MAP3K14 and Kinase-Dead (K429A) mutant proteins available with >95% purity. |
| In vitro kinase assay optimization with unstable kinase domains | Recombinant active kinase domain optimized for stability and sequence-verified by MS. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live MAP3K14 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAP3K14 (NIK) therapeutics is intensifying, with major players shifting focus from traditional small molecule kinase inhibitors to targeted protein degradation (PROTACs). As first-generation systemic kinase inhibitors face narrow therapeutic windows due to liver toxicity and off-target safety profiles, the next wave of R&D is targeting tissue-specific delivery and selective degradation to overcome kinase-independent scaffolding functions of MAP3K14.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Amgen, Genentech, Biogen | Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis | Kinase Selectivity Profiling (Need MAP3K family panel proteins) |
| PROTACs / Degraders | Kymera Therapeutics, Arvinas | Multiple Myeloma, B-cell Lymphomas | Ternary Complex Formation Assay (Need high-purity active MAP3K14) |
| Gene Therapy / RNAi | Academic Institutions | Inflammatory Bowel Disease (IBD) | In vitro Knockdown Validation (Need validated siRNA & Lentivirus) |